Introduction {#S1}
============

The anterior cingulate cortex (ACC) is closely related to the occurrence and development of depression. The ACC occupies the rostral portions of Brodmann areas 24, 25, 32, and 33, and is activated by diverse tasks, ranging from emotion processing and regulation to attention and cognitive control ([@B5]). Many previous studies have confirmed the significant association of the ACC, especially the subgenual ACC, with the processing of negative emotions. The pregenual ACC is considered to be associated with cognitive functions such as social cognition, including theory of mind tasks and conflict monitoring ([@B5]; [@B6]; [@B4]).

Perimenopausal depression is a mental disorder that first occurs in women during the perimenopausal period and is mainly characterized by symptoms of hypothymia, anxiety, nervousness, and loss of interest, accompanied with autonomic and endocrine dysfunction, especially recession of the gonads. Women with severe symptoms may have a tendency to commit suicide. A meta-analysis has shown that women in the perimenopausal period were particularly vulnerable to anxiety or depression, and had more severe symptoms than women in the premenopausal period ([@B2]). However, the pathophysiological mechanisms of perimenopausal depression are still unknown.

Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central nervous system. It combines with GABA receptors and inhibits excitatory neural activity. Abnormal GABA metabolism plays an important role in the pathogenesis of mental disorders such as depression and schizophrenia ([@B10]; [@B14]). An increasing body of preclinical and clinical evidence has proved that a close relationship exists between GABA and depression. Magnetic resonance spectroscopy (MRS) is a non-invasive technique for quantifying metabolites in the brain. MRS has been successfully applied in studies of depression and has detected changes in many metabolites in different brain regions ([@B13]). MRS plays an important role in exploring the treatments and mechanisms of depression. However, due to the chemical shift and the scalar coupling effect, the GABA spectrum overlaps with signals of other major metabolites. It is therefore difficult to detect GABA by using conventional ^1^H-MRS. An improved MRS method---MEGA-PRESS, based on partially refocused J-couplings---has been used to detect GABA in studies of healthy brains and psychiatric diseases.

In this study, we used the MEGA-PRESS technique to detect GABA in the anterior cingulate cortex (ACC) of perimenopausal women. The Totally automatic robust quantitation in nuclear MR (TARQUIN) software was used as the post-processing method to calculate GABA concentrations. We aimed to characterize the pathophysiological mechanisms of perimenopausal depression by determining whether changes in GABA concentrations in the ACC were associated with perimenopausal anxiety/depression.

Materials and Methods {#S2}
=====================

Participants {#S2.SS1}
------------

We recruited 131 perimenopausal women. After the exclusion of 11 participants, 120 participants remained. The inclusion criteria for the experimental group were as follows: (1) women in the perimenopausal stage, as defined by the Stages of Reproductive Aging Workshop ([@B18]), i.e., a persistent ≥7-day difference in menstrual cycle length in consecutive cycles (persistence was defined as recurrence within 10 cycles of the first cycle with variable length), and (2) education up to junior high school level or above. The exclusion criteria were as follows: (1) GABA values could not be detected (6 of the 131 participants were excluded due to this reason), (2) diagnosis of a somatic disease (hypertension or diabetes mellitus); (3) presence of a hypothalamic-pituitary-adrenal axis or thyroid disease; (4) history of depression or other related mental illnesses, or presence of dementia or other organic mental disorders; (5) use of oral contraceptives or hormone therapy within 3 months of entering the study; (6) a history of non-depressive disorders in the participant or a family member (including immediate family by blood and collateral blood relatives within three generations); (7) smoking and/or dependence on alcohol; and (8) poor GABA quality (5 of the 131 participants were excluded because of this reason) ([Figure 1](#F1){ref-type="fig"}).

![Flow chart and comparisons of GABA levels between the normal, anxiety, and depression groups.](fnins-13-00785-g001){#F1}

### Estrogen Measurements {#S2.SS1.SSS1}

A fasting blood specimen (3 mL) was collected into a 5-mL sterile plain tube without anticoagulant at 9:00--11:00 a.m. on the second or third day of the menstrual cycle. However, if a timely sample could not be obtained (as was the case for the late stage perimenopausal women), a fasting sample was taken when the endometrium was \<5 mm thick as determined using transvaginal Doppler ultrasonography. In this study, estrogen levels fluctuated during the perimenopausal period, but the overall trend was downward.

This study was approved by the ethics committee of the Shanghai Sixth People's Hospital, Shanghai Jiao Tong University), and all participants signed informed consent forms before being entered into the study.

MRI and MRS Analyses {#S2.SS2}
--------------------

In all subjects, MR data were acquired using a 3.0-T MR scanner (MAGETOM, Verio, Siemens Healthcare, Erlangen, Germany) equipped with a 32-channel phased-array head coil as the transmitting and receiving coils. First, a T1-weighted turbo field echo sequence was used to obtain high-resolution three-dimensional (3D) axial images of the brain structure, with the following scanning parameters: field of vision (FOV), 230 mm; repetition time (TR)/echo time (TE), 1500/2.96 ms; flip angle, 9°; voxel size, 0.9 mm × 0.9 mm × 1 mm; slice thickness, 1 mm; and distance factor, 50%. The MEGA-PRESS sequence was used to detect GABA in the regions of interest (ROIs), with the following scanning parameters: TE, 68 ms; TR, 1500 ms; acquisition bandwidth, 1200 Hz; pulse placement, 1.9 ppm, and number of excitations, 64 on and 64 off. Unsuppressed water was used for water scaling and correction of frequency and phase. The spectra were fitted using TARQUIN software ([@B20]; [@B12]; [@B8]). GABA peaks were quantified calculated using the water-scaled method, as described previously ([@B20]; [@B12]; [@B8]).

A radiologist with 10 years of experience placed two ROIs measuring 2 cm × 2 cm × 2 cm each bilaterally in the subgenual ACC in the sagittal plane and adjusted them accordingly in the coronal and axial planes. The average GABA value of the right and left sides (ROIs) was calculated. The edges of all ROIs were positioned to avoid the lateral ventricles and skull. All images were post-processed by the same radiologist with 10 years of experience, and the TARQUIN software was used to calculate GABA concentrations in the ROIs ([Figure 2](#F2){ref-type="fig"}).

![The region of interest in the anterior cingulate cortex on MEGA-PRESS in the axial, sagittal, and coronal planes. TARQUIN edited spectrum GABA in the normal, anxiety, and depression groups. The edited spectrum of the premenopausal and postmenopausal GABA levels located at 3.0 ppm.](fnins-13-00785-g002){#F2}

Gray matter and white matter tissue proportion of interest has been evaluated for each patient using manual segmentation available in ITK-SNAP^[1](#footnote1){ref-type="fn"}^, where the bounding box was redrawn from the saved planning volume of interest.

### Quality Control {#S2.SS2.SSS1}

In order to gain a high success ratio acquiring GABA spectra, we defined a pre-requirement for performing GABA acquisition: magnetic field inhomogeneity \<15 Hz for the defined ROI. After the GABA acquisition, we visually inspected the spectra, and the quality control parameters for spectral fitting were reviewed to verify that the spectra were not qualitatively abnormal. All full widths at half maximum were ≤0.12 ppm. Poorly fitted spectra higher than 20% of the GABA estimate were excluded from further analysis, and this led to the exclusion of 5 of the 131 participants.

Statistical Analysis {#S2.SS3}
--------------------

For all statistical tests, the level of significance was set at *P* \< 0.05. The following analyses were carried out ([Figure 3](#F3){ref-type="fig"}).

![Two-way repeated ANOVA was used to compare the difference between normal group, anxiety group and depression group at different times. The ANOVA for repeated measures is used to perform the data analysis. Interaction between group effects and time effects was significant (*F* = 6.642, *p* \< 0.01), the main effect of the group was significant (*F* = 4.473, *p* \< 0.05), and the time effect was significant (*F* = 49.251, *p* \< 0.001). (1) The main effect showed no statistical difference between any two groups in the three groups at the start time point, but there was a statistical difference between the two groups in the follow-up time point (*p* \< 0.05). (2) The time effect shows that there are differences between the two time points in the normal group, there are differences between the two time points of the anxiety group, and there are also differences between the two time points in the depression group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001.](fnins-13-00785-g003){#F3}

1.  Two-way repeated ANOVA with time (pre-menopausal, post-menopausal) and three groups (normal, depression, anxiety group) was used to compared changes GABA with time and groups. Both of the main effect of the group and the time effect were done.

    Main effect compared the difference between normal group, depression group and anxiety group at premenopausal stage (i.e., normal group vs. anxiety group, normal group vs. depression group, and anxiety group vs. depression group). It also compared the difference between the three groups at postmenopausal stage.

    Time effect was used to compare the difference of pre- and postmenopausal GABA concentrations in the normal group (*n* = 71), anxiety group (*n* = 30), and depression group (*n* = 19).

2.  The Pearson correlation coefficient was used to analyze the correlation of GABA with the Hamilton Anxiety Scale (HAMA)-14 scores in the anxiety group and with the Hamilton Depression Scale (HAMD)-17 scores in the depression group. A two-tailed test of significance was used, with a *P* value \<0.05 considered statistically significant.

3.  Receiver operating characteristic (ROC) curves and the area under the curve (AUC) were calculated to evaluate the diagnostic performance of GABA concentration in the control, anxiety, and depression groups.

4.  Retrospective calculated the gray matter/white matter ratio, as this ratio changes at the two time points (beginning and follow up), one-way ANOVA was used to compare the difference.

Results {#S3}
=======

General Information {#S3.SS1}
-------------------

The 120 women remaining in this study were followed up for 18--24 months. All women underwent MRS with a 3.0-T MR scanner assessed before and after menopause. The participants were divided into three groups: normal group (*n* = 71), anxiety group (*n* = 30), and depression group (*n* = 19). These diagnoses were based on the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) and were made by two psychiatrists (with 8 and 10 years of experience). These two psychiatrists also assessed the HAMA-14 and HAMD-17 scores before and after menopause. HAMD-17 scores ≥ 17 suggest depression, while HAMA-14 scores \> 14 suggest anxiety ([Figure 1](#F1){ref-type="fig"}).

The general information of the three groups is displayed in [Table 1](#T1){ref-type="table"}. Blood pressure, blood glucose and triglyceride levels, and body mass index did not significantly differ between the three study groups (*P* \> 0.05; [Table 1](#T1){ref-type="table"}).

###### 

General information.

                                            **Normal group**   **Anxiety group**   **Depression group**   ***P***                                             
  ----------------------------------------- ------------------ ------------------- ---------------------- --------- -------- -------- ----------- ----------- -----------
  Patients (n)                              71                                     30                               19                --          --          --
  Age (years)                               46.80              1.98                47.57                  1.99      47.68    1.86     0.076       0.085       0.839
  Systolic pressure (mmHg)                  80.83              7.46                86.7                   3.82      87.79    4.72     \<0.05^∗^   \<0.05^∗^   0.559
  Diastolic pressure (mmHg)                 122.96             7.96                125.83                 6.16      126.74   6.73     0.075       0.049       0.676
  Triglyceride (mmol/L)                     1.414              0.306               1.551                  0.237     1.452    0.274    0.030^∗^    0.612       0.238
  BMI (kg/m^2^)                             22.910             1.923               23.967                 2.950     23.595   3.027    0.046       0.272       0.599
  Premenopausal Serum estradiol (mmol/L)    83.170             31.204              81.142                 33.245    92.588   30.500   0.769       0.251       0.219
  Postmenopausal Serum estradiol (mmol/L)   75.858             17.334              63.478                 22.195    54.020   18.483   0.003       \<0.01^∗^   0.089
  Premenopausal HAMD score                                                                                          4.789    0.713    0.462       0.382       0.738
  Postmenopausal HAMD score                                                                                         20.737   2.579    \<0.05^∗^   \<0.05^∗^   \<0.05^∗^
  Premenopausal HAMA score                                                         3.700                  1.088                       0.126       0.140       0.868
  Postmenopausal HAMA score                                                        18.1                   3.356                       \<0.05^∗^   \<0.05^∗^   \<0.05^∗^

P1, normal vs. anxiety group, independent-samples

t

-test; P2, normal vs. depression group, independent-samples

t

-test; P3, anxiety vs. depression group, independent-samples

t

-test.

∗

P

\< 0.05 was statistically significant. BMI, body mass index; HAMD, hamilton depression scale; HAMA, hamilton anxiety scale.

MRS Data {#S3.SS2}
--------

By means of the MEGA-PRESS sequence, we successfully acquired edited spectra of GABA from the ACC region in 120 subjects.

### GABA {#S3.SS2.SSS1}

The two-way repeated ANOVA results showed that the interaction between group effects and time effects was significant (*F* = 6.642, *p* \< 0.01), the main effect of the group was significant (*F* = 4.473, *p* \< 0.05), and the time effect was significant (*F* = 49.251, *p* \< 0.001) ([Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}).

###### 

Two-way repeated ANOVA was used to compare the difference between normal group, anxiety group and depression group at different times.

  **Group**          **Beginning GABA**   **Follow up GABA**   **F time**    **F group**   **F time × group**
  ------------------ -------------------- -------------------- ------------- ------------- --------------------
  Normal group       2.242 + 0.250        2.172 + 0.235        49.251^∗∗∗^   4.473^∗^      6.642^∗∗^
  Anxiety group      2.236 + 0.180        2.059 + 0.201                                    
  Depression group   2.202 + 0.172        1.923 + 0.213                                    

Interaction between group effects and time effects was significant (

F

= 6.642,

p

\< 0.01), the main effect of the group was significant (

F

= 4.473,

p

\< 0.05), and the time effect was significant (

F

= 49.251,

p

\< 0.001).

∗

P

\< 0.05;

∗∗

P

\< 0.01;

∗∗∗

P

\< 0.001.

###### 

Difference between normal group, depression group and anxiety group at premenopausal and postmenopausal time.

                                                    **Mean Difference**   **Standard**                **95% Confidence interval**   
  ----------- ------------------ ------------------ --------------------- -------------- ------------ ----------------------------- ---------
  Beginning   Normal group       Anxiety group      0.006                 0.049          0.907        --0.091                       0.102
                                 Depression group   0.040                 0.058          0.495        --0.075                       0.154
              Anxiety group      Normal group       --0.006               0.049          0.907        --0.102                       0.091
                                 Depression group   0.034                 0.066          0.606        --0.096                       0.164
              Depression group   Normal group       --0.040               0.058          0.495        --0.154                       0.075
                                 Anxiety group      --0.034               0.066          0.606        --0.164                       0.096
  Follow up   Normal group       Anxiety group      0.113^∗^              0.049          0.022^∗^     0.017                         0.210
                                 Depression group   0.245^∗^              0.058          0.000^∗∗∗^   0.131                         0.360
              Anxiety group      Normal group       −0.113^∗^             0.049          0.022^∗^     --0.210                       --0.017
                                 Depression group   0.132^∗^              0.066          0.047^∗^     0.002                         0.262
              Depression group   Normal group       −0.245^∗^             0.058          0.000^∗∗∗^   --0.360                       --0.131
                                 Anxiety group      −0.132^∗^             0.066          0.047^∗^     --0.262                       --0.002

The simple effect showed no statistical difference between any two groups in the three groups at the start time point, but there was a statistical difference between the two groups in the follow-up time point (

p

\< 0.05).

∗

P

\< 0.05;

∗∗∗

P

\< 0.001.

###### 

Difference between premenopausal (time 1) and postmenopausal time (time 2) of the normal group, depression group and anxiety group.

                             **Mean Difference**   **Std.**                **95% Confidence interval**   
  ------------------ --- --- --------------------- ---------- ------------ ----------------------------- ---------
  Normal group       1   2   0.070^∗^              0.028      0.014^∗^     0.015                         0.125
                     2   1   −0.070^∗^             0.028      0.014^∗^     --0.125                       --0.015
  Anxiety group      1   2   0.178^∗^              0.043      0.000^∗∗∗^   0.092                         0.263
                     2   1   −0.178^∗^             0.043      0.000^∗∗∗^   --0.263                       --0.092
  Depression group   1   2   0.276^∗^              0.054      0.000^∗∗∗^   0.169                         0.383
                     2   1   −0.276^∗^             0.054      0.000^∗∗∗^   --0.383                       --0.169

The simple effect shows that there are differences between the two time points in the normal group, there are differences between the two time points of the anxiety group, and there are also differences between the two time points in the depression group.

∗

P

\< 0.05;

∗∗∗

P

\< 0.001.

1.  The main effect showed no statistical difference between any two groups in the three groups at the premenopausal time point, but there was a statistical difference between the two groups in the follow-up time point (*p* \< 0.05).

    The postmenopausal GABA levels significantly differed between the normal vs. anxiety group (*P* = 0.022), normal vs. depression group (*P* \< 0.001), and anxiety vs. depression group (*P* = 0.047). The postmenopausal GABA levels were significantly lower in the depression group than in the anxiety group and were significantly lower in both these groups than in the normal group.

    The premenopausal GABA levels did not significantly differ between the normal vs. anxiety group (*P* = 0.907), normal vs. depression group (*P* = 0.495), and anxiety vs. depression group (*P* = 0.606).

2.  The time effect shows that there are differences between the two time points in the normal group, there are differences between the two time points of the anxiety group, and there are also differences between the two time points in the depression group. This means there is difference between postmenopausal groups, and GABA decreased with time.

    The postmenopausal GABA levels were significantly lower than the premenopausal levels in the normal, anxiety, and depression groups (*P* = 0.014, \<0.001, and \<0.001, respectively).

### Pearson Correlation Analysis {#S3.SS2.SSS2}

Pearson correlation analysis revealed the following: (1) The premenopausal GABA levels were not significantly correlated with the HAMA-14 scores in the anxiety group (*r* = 0.176, *P* = 0.352) or with HAMD-17 scores in the depression group (*r* = −0.191, *P* = 0.433). (2) The postmenopausal GABA levels were significantly correlated with the HAMA-14 score in the anxiety group (*r* = −0.365, *P* = 0.048), but not with the HAMD-17 score in the depression group (*r* = −0.428, *P* = 0.068; [Figures 4](#F4){ref-type="fig"}--[7](#F7){ref-type="fig"} and [Table 5](#T5){ref-type="table"}).

![Pearson correlation coefficients for premenopausal GABA levels in the anxiety group and the premenopausal HAMA-14 scores.](fnins-13-00785-g004){#F4}

![Pearson correlation coefficients for postmenopausal GABA levels in the anxiety group and the postmenopausal HAMA-14 scores.](fnins-13-00785-g005){#F5}

![Pearson correlation coefficients for premenopausal GABA levels in the depression group and premenopausal HAMD-17 scores.](fnins-13-00785-g006){#F6}

![Pearson correlation coefficients for postmenopausal GABA levels in the depression group and postmenopausal HAMD-17 scores.](fnins-13-00785-g007){#F7}

###### 

Pearson correlation coefficients for HAMA scores and GABA of anxiety group, Pearson correlation coefficients for HAMD scores and GABA of depression group.

                     **Premenopausal**                   **Postmenopausal**                                                                     
  ------------------ ------------------- --------------- -------------------- -------------------- ---------------- --------------- ----------- -------
  Anxiety group      3.700 + 1.088       2.236 + 0.180   0.176                0.352                18.1 + 3.356     2.059 + 0.201   −0.365^∗^   0.048
                                                                                                                                                
                     **Premenopausal**                                        **Postmenopausal**                                                
                     **HAMD score**      **GABA**                                                  **HAMD score**   **GABA**                    
                                                                                                                                                
  Depression group   4.789 + 0.713       2.202 + 0.172   −0.191               0.433                20.737 + 2.579   1.923 + 0.213   −0.42857    0.068

Two-tailed Pearson correlation test of significance was used.

∗

Correlations were significant at the 0.05 probability level.

Receiver operating characteristic curve and AUC results: The postmenopausal GABA diagnostic performance in normal and mental disorders (both anxiety and depression) was as follows: AUC value 0.703 (*P* \< 0.001). Postmenopausal GABA diagnostic performance in anxiety and depression was as follows: AUC value 0.677 (*P* = 0.038). The ratio of GABA decline to premenopausal GABA diagnostic performance in normal and mental disorders (both anxiety and depression) was as follows: AUC value 0.683 (*P* \< 0.001). The ratio of GABA decline to premenopausal GABA diagnostic performance in anxiety and depression was as follows: AUC value 0.774 (*P* = 0.001; [Figure 8](#F8){ref-type="fig"}).

![Receiver operating characteristic (ROC) curves and area under the curve (AUC) value were calculated to assess the diagnostic performance of GABA in the normal, anxiety, and depression groups.](fnins-13-00785-g008){#F8}

### Gray Matter/White Matter Ratio {#S3.SS2.SSS3}

There is no significant difference between groups and times; gray matter/white matter ratio did not drive the GABA comparison results ([Table 6](#T6){ref-type="table"}).

###### 

Gray matter/white matter ratio comparison between three groups (normal group, anxiety group, and depression group) at beginning time and follow up time.

                                 **Number**   **Lesion**   **Comparison between groups**                                              
  ----------- ------------------ ------------ ------------ ------------------------------- -------------------------------- --------- -------
  Beginning   Normal group       71           0.774        0.013                           Anxiety group Normal group       --0.176   0.860
              Anxiety group      30           0.773        0.013                           Depression group Normal group    1.686     0.094
              Depression group   19           0.779        0.015                           Depression group Anxiety group   1.616     0.109
  Follow up   Normal group       71           0.778        0.019                           Anxiety group Normal group       --0.929   0.355
              Anxiety group      30           0.774        0.017                           Depression group Normal group    0.686     0.494
              Depression group   19           0.774        0.019                           Depression group Anxiety group   0.086     0.932

There is no significant difference between groups and times of Gray matter/white matter ratio.

GABA SNR%SD were calculated between groups and two time points, there is no significant difference.

Discussion {#S4}
==========

In this study, we have provided preliminary evidence that GABA levels in the ACC region of perimenopausal women with depression were significantly lower after menopause and were significantly lower than the levels in the control group (*P* \< 0.05). This finding suggests that a reduction in GABA levels in the ACC is associated with the pathophysiological mechanism of perimenopausal depression, and that there might be a lack of GABA in the perimenopausal period. The study also found that after menopause, the concentration of GABA was significantly lower in the depression group than in the anxiety group, and significantly lower in the anxiety group than in the normal group. This further suggested an association between a reduction in GABA levels and depression. We also observed dynamic changes in GABA levels during the transition from the premenopausal to the postmenopausal period.

Many investigators have focused on the relationship between GABA levels and depression. GABA concentrations in the plasma and cerebrospinal fluid of depressive patients are lower than those in healthy controls. [@B17] found that GABA-neuron density in the auditory cerebral cortex is reduced in subjects with major depressive disorder. Using MRS studies, [@B9] found lower GABA levels in the prefrontal cortex in subjects with major depression than in healthy controls. Many studies have found that patients with depression have lower GABA levels in the occipital lobe and ACC than do healthy controls ([@B15]; [@B1]). [@B15] have suggested that GABA concentrations vary among the different subtypes of depression and that a change in the ratio of excitatory--inhibitory neurotransmitter levels might be associated with abnormal brain function. In investigations of female physiological cycles related with depression, [@B11] found that GABA levels in the ACC, prefrontal lobe, and left basal ganglia region were significantly reduced in women with premenstrual dysphoric disorder. [@B19] found that GABA levels in the ACC and medial prefrontal lobe were decreased in postmenopausal women. In our study, we also detected reduced GABA levels in the ACC of perimenopausal women with depression, which was consistent with the results of the above studies. However, GABA was too low to be detected in some participants.

An imbalance of the limbic-cortical-striatal-pallidal-thalamic loop is the generally acknowledged neurological model of depression. The activity of the anterior cingulate gyrus and dorsal lateral frontal lobe has been shown to be decreased in depressive patients. [@B19] detected significantly low GABA levels in the ACC/medial prefrontal cortex of postmenopausal women with depression. [@B3] found that after repetitive transcranial magnetic stimulation, the GABA levels in the medial prefrontal cortex significantly increased. Therefore, in this study, we selected the ACC region as the ROI, as this region is closely related with emotional function. We did not choose the occipital lobe as in the study by [@B1] because the size of the ROI in our study was relatively large, and ROIs placed in the occipital lobe can be easily disturbed by other structural signals in the base of the skull. [@B9] detected reduced GABA levels in the prefrontal regions in patients with major depressive disorder, including parts of the ACC, but the GABA values in their study were lower than the GABA values in this study, possibly because of differences in ROI sizes, channels of the head coil, and calculation methods. We retrospectively calculated the gray matter/white matter ratio, as this ratio changes at the two time points (beginning and follow up); there was no significant difference between groups and times. Gray matter/white matter ratio did not drive the GABA results.

There are some limitations to this study. First, this is a cohort study, and the sample size needs to be increased in future. The follow-up period was relatively short. To explain the relationship between GABA levels and the pathogenesis of perimenopausal depression, more experiments need to be performed. GABA spectroscopy was poor due to movement, and GABA spectroscopy could not be acquired due to the participant requesting to end the scan prematurely. Furthermore, we only selected the ACC as the ROI; the prefrontal cortex and other brain regions related to emotional circuits were not included in this study. The differences between the left and right ROIs were not assessed. The manually prescribed ROIs were subjective and could have led to deviations in the results of different subjects. Moreover, it has been suggested that the GABA levels in the brain decrease with age ([@B7]). During the perimenopausal period, hormone levels fluctuate significantly. Studies have suggested that decreased estrogen levels affect perimenopausal depression ([@B16]). And the gray matter/white matter ratio was retrospectively calculated, and a small amount of cerebrospinal fluid was not considered and may lead to some small deviation.

Conclusion {#S5}
==========

In summary, this study examined the changes in the GABA levels in the ACC region in perimenopausal women with depression and anxiety as well as healthy women (controls). The results suggested that the GABA levels in the ACC decreased during the perimenopausal period, and that this decrease was closely associated with depression and anxiety. We calculated GABA concentrations by using the MEGA-PRESS sequence; the results were highly reliable and stable. Advances in MRS technology will be important in the exploration of pathogenesis and the development of targeted drugs for perimenopausal depression.
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